Use of the Corus® CAD Gene Expression Test for Assessment of Obstructive Coronary Artery Disease Likelihood in Symptomatic Non-Diabetic Patients

Published

Journal Article (Review)

The determination of the underlying etiology of symptoms suggestive of obstructive coronary artery disease (CAD, ≥50% stenosis in a major coronary artery) is a common clinical challenge in both primary care and cardiology clinics. Usual care in low to medium risk patients often involves a family history, risk factor assessment, and then stress testing with or without non-invasive imaging. If positive, this is often followed by invasive coronary angiography (ICA). Despite extensive adoption of this usual care paradigm, more than 60% of patients referred for angiography do not have obstructive CAD. In order to robustly identify those symptomatic patients without obstructive CAD, who can avoid subsequent cardiac testing and look elsewhere for the cause of their symptoms, a recently described whole blood gene expression score (GES: Corus® CAD, CardioDx, Inc., Palo Alto, CA) has been developed and validated in two multi-center trials. This paper reviews the published literature and assessments by independent parties regarding the analytical and clinical validity as well as the clinical utility of the Corus® CAD test.

Full Text

Duke Authors

Cited Authors

  • Vargas, J; Lima, JAC; Kraus, WE; Douglas, PS; Rosenberg, S

Published Date

  • September 16, 2013

Published In

Electronic International Standard Serial Number (EISSN)

  • 2157-3999

Digital Object Identifier (DOI)

  • 10.1371/currents.eogt.0f04f6081905998fa92b99593478aeab

Citation Source

  • Scopus